A Vanderbilt researcher has been awarded $6.2 million to study the effect of opioids on the brain.
With opioid prescriptions plummeting and no more pharma companies to sue, America's drug warriors are running out of bogeymen ...
A good night's sleep often sets the stage for a positive day. But for the nearly quarter of American adults struggling with ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
After reading a recent Sun-Times investigation on opioid deaths among a generation of Black men, WBEZ editor Alden Loury ponders the role of racism and segregation in those deaths.
2d
We are collecting data on people who have sought ibogaine treatment all around the world so we can start to collect a very ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
WSYR Syracuse on MSN3d
Newly FDA-approved non-opioid painkiller is first of its kind in over 20 yearsFor the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain.
Researchers have identified how CBD interacts with cannabinoid receptors to mitigate the negative effects of THC, the psychoactive component of cannabis.
Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...
The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback